GSK PLC
GSK: XLON (GBR)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
GBX 2,836.00 | Vsf | Kcrkjtzwc |
Undervalued GSK Posts Strong Q3, as Zantac Litigation Concerns Appear Overemphasized
GSK reported better-than-expected third-quarter results largely driven by strong sales of COVID-19 treatment Xevudy. However, given the likely decline in Xevudy sales over the next year due to the pandemic receding and strong competing oral COVID-19 treatments, we don’t expect any major changes to our GSK fair value estimate based on the solid results.